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Abstract
Background: In 2005, Ghana replaced chloroquine with artemisinin-based combination therapy as the first-line
treatment for uncomplicated malaria. The aim of this work was to determine for the first time, polymorphisms in the
putative pfATPase6 and pftctp, pfmdr1, pfcrt genes in Ghanaian isolates, particularly at a time when there is no report
on artemisinin resistance in malaria parasites from Ghana. The sensitivity of parasite isolates to anti-malaria drugs
were also evaluated for a possible association with polymorphisms in these genes.
Methods: The prevalence of point mutations in the above Plasmodium falciparum genes were assessed from filter-paper
blood blot samples by DNA sequencing. In vitro drug sensitivity test was carried out on some of the blood samples from
volunteers visiting hospitals/clinics in southern Ghana using a modified version of the standard WHO Mark III micro-test.
Results: All successfully tested parasite isolates were sensitive to artesunate; while 19.4%, 29.0% and 51.6% were
resistant to quinine, amodiaquine and chloroquine respectively. The geometric mean of IC50 value for artesunate
was 0.73 nM (95% CI, 0.38-1.08), amodiaquine 30.69 nM (95% CI, 14.18-47.20) and chloroquine 58.73 nM (95% CI,
38.08-79.38). Twenty point mutations were observed in pfATPase6 gene, with no L263E and S769N. All mutations
found were low in frequency, except D639G which was observed in about half of the isolates but was not
associated with artesunate response (p = 0.42). The pftctp gene is highly conserved as no mutation was observed,
while CVIET which is chloroquine-resistant genotype at codon 72-76 of the pfcrt gene was identified in about half
of the isolates; this was consistent with chloroquine IC50 values (p = 0.001). Mutations were present in pfmdr1 gene
but were not associated with artemisinin response (p = 1.00).
Conclusion: The pfATPase6 gene is highly polymorphic with D639G appearing to be fixed in Ghanaian isolates.
These may just be spontaneous mutations as all parasite isolates that were tested displayed satisfactory in vitro
response to artesunate. However, there is no improvement in susceptibility of the parasites to chloroquine five
years after its proscription.
Background
Malaria remains a major public health concern in the
world decades after Laveran discovered its causative
agent in 1880. An estimated 247 million clinical cases
occur every year across the globe, with about 881,000
deaths annually [1]. This quandary from malaria is partly
due to the emergence and spread of Plasmodium falci-
parum parasites that are resistant to conventional
anti-malaria drugs in almost all endemic countries [2,3].
Artemisinin derivatives, which are fast acting and kill all
stages including young gametocytes of multi-drug resis-
tant malaria parasites [4,5], have been recommended by
the World Health Organization (WHO) in the form of
combination therapy for the treatment of uncomplicated
malaria to enhance its therapeutic efficacy as well as
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malaria parasite [6].
Studies in China, Thailand and Cambodia where oral
artemisinin-based monotherapies have long been used,
reported on reduced susceptibility to artemisinin deriva-
tives in some malaria parasites [7-9]. Due to the fact that
multi-drug resistant parasites originated from this area
[10], diligent surveillance aimed at monitoring suscept-
ibility of malaria parasites to artemisinin derivatives and
the partner drugs in endemic areas is prudent. Pieces of
evidence demonstrate that the sarco-endoplasmic reticu-
lum calcium-dependent (SERCA) ATPase protein
encoded by pfATPase6 and the translationally controlled
tumour protein (TCTP) encoded by pftctp are involved
in artemisinin activity [11,12].
Uhlemann et al [13] in their study observed that L263E
replacement in pfATPase6 gene abolishes inhibition of
artemisinins in P. falciparum. A subsequent study in
French Guiana revealed that S769N mutation in pfAT-
Pase6 was associated with high artemether IC50 values
[14]. In this same study, a combination of two mutations
E431K and A623E in a clinical isolate from Senegal
showed considerable increase in artemether IC50 [14],
s u g g e s t i v et h a tt h e s ep o i n tm u t a t i o n sc o u l db eu s e di n
molecular monitoring of artemisinin derivatives to com-
plement continuing in vitro surveillance. Until recently, it
was thought that few mutations are present in the pfAT-
Pase6 gene as some studies have revealed polymorphisms
in this putative gene even though their roles are not
known [15,16]. Related studies have averred that while
mutant haplotypes of pfmdr1 and pfcrt genes in some
isolates conferred chloroquine resistance, they however
increase parasite susceptibility to artemisinin derivatives
[17,18].
In the year 2005, Ghana deployed artemisinin-based
combination therapy (ACT) as the first-line treatment for
malaria [19]; however, oral artemisinin-based monothera-
pies are also registered, and in an uncontrolled use by the
general public [20]. In spite of this, there is no report of
suspected artemisinin resistance in P. falciparum isolates
from Ghana yet, and no work has been carried out on
the pfATPase6 gene as a molecular marker in Ghana. In
this study, the susceptibility of P. falciparum parasites to
artesunate, amodiaquine, chloroquine and quinine was
evaluated in vitro for Ghanaian isolates; point mutations
in the pfATPase6, pftctp,a n dpfmdr1 genes were also
examined, creating a picture in time before any report of
resistance, and if they could be associated with differen-
tial responses to the anti-malaria drugs above. In addi-
tion, the putative pfcrt gene which is implicated in
chloroquine resistance was evaluated for the status quo
in the parasite isolates after five years of chloroquine pro-
scription, as in the case of Malawi [21,22].
Methods
Study design and sites
This hospital/clinic based cross-sectional survey was car-
ried out from August to October 2010. Seven commu-
nities in southern Ghana, Okyereko, Buduatta, Nyanyano,
Apam, Kasoa, Achimota and Maamobi were selected
based on the availability of a health facility, and proximity
to Noguchi Memorial Institute for Medical Research
(NMIMR), Accra-Ghana in order to reduce logistical con-
straints so that the blood samples will be cultured within
eight hours after collection from participants. These areas
were also purposively selected based on the fact that there
is an already established acquaintance with the health cen-
tres and the community members for other on-going pro-
jects in NMIMR. Malaria transmission in Ghana is stable
throughout the year with seasonal variation, while studies
have shown that entomological inoculation rate in some
of the study communities range from 0-20 infective bites/
night [23,24].
Study participants were recruited from persons attend-
ing health centres in the above-mentioned communities.
They included those who have been diagnosed with
uncomplicated malaria on the basis of their clinical symp-
toms and by Rapid Diagnostic Test (RDT) kit (Malaria Ag
Pf/Pan, Immunochromatographic assay, BIOLINE SD
Rapid Test, STANDARD DIAGNOSTICS, INC, Haryana,
India). All RDT-positive participants were given the
appropriate treatment by the doctors in the respective
health centres immediately after sample collection.
Sample collection
A total of 146 strip filter-paper (ADVANTEC
®) blood
blots as well as thick and thin blood films were prepared
from both P. falciparum antigen positive and negative
RDT tested volunteers using finger-pricked blood sam-
ples. The filter-paper blood blots were air-dried and
packaged into individual re-sealable plastic bags with
silica gel desiccant and kept at 4°C until ready for geno-
mic DNA extraction, while the slides were stained with
Giemsa to adjust parasitaemia before culturing. Plain
vacutainer tubes that were used for the blood collection
were coated with 0.5 ml CPD-adenine buffer, an anticoa-
gulant that can keep parasite isolates in good condition
at room temperature for about eight hours [25]. Thirty-
eight of the RDT-positives provided 3 ml of venous
blood samples which were aseptically collected into the
above tubes. These were transported to the laboratory
within four hours of collection for drug sensitivity tests.
Drug sensitivity tests
Malaria parasite culture medium
Hypoxanthine (SIGMA-Aldrich) solution was prepared
by dissolving 54.4 mg in 40 ml distilled water with
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RPMI 1640 with 2 mM glutamine and 25 mM HEPES
(GIBCO-Invitrogen), with 25 μg/ml gentamicin solution
(SIGMA-Aldrich). The culture medium comprised the
above basal medium with 10% Daigo’sG F 2 1( W a k o
Pure Chemical Industries, Japan), supplemented with
150 μM hypoxanthine and 5% normal human serum.
This complete culture medium was termed HGRPMI
[26].
Anti-malaria drugs tested
The anti-malaria drugs tested were appropriately recon-
stituted. 10 mM stock solution each of artesunate, amo-
diaquine dihydrochloride dihydrate (Sigma
®)a n d
chloroquine diphosphate salt (Sigma
®) were initially pre-
pared in 5 ml of phosphate buffered saline (PBS), while
quinine (Sigma
®) was dissolved with 70% ethanol. Final
drug concentrations ranged from 0.16-160 nM for arte-
sunate, 1.25-1280 nM for amodiaquine and chloroquine,
and 10-10,240 nM for quinine. These were prepared
using HGRPMI. All reagents and culture medium were
filter-sterilized through 0.2 μmA c r o d i s c
® filter mem-
brane after preparation.
Malaria parasite cultures
The sensitivity of Ghanaian isolates to the anti-malaria
drugs was assessed by a modification of the standard
WHO Mark III micro-test [27]. In vitro assays were car-
ried out on samples with parasitaemia > 0.3% by micro-
scopy, within eight hours after collection. The blood
samples in CPD-adenine buffer were washed three times
with basal medium (RPMI 1640), removing the superna-
tant and white blood cell interface after every wash at
1800 rpm for 6 min. Erythrocytes were re-suspended at
1 : 1v o l u m ei nH G R P M I .T h es t a r t i n gp a r a s i t a e m i aw a s
adjusted to 0.3-2.0% when required, by the addition of
fresh uninfected erythrocytes. Each well of a 96-well tissue
culture plate was filled with 90 μl drug solution of appro-
priate concentration plus 10 μl parasite suspension of
about 5% haematocrit [28,29]. Control wells (with parasi-
tized or uninfected erythrocytes) contained drug-free med-
ium. Cultures of P. falciparum FCR3/FMG (ATCC
Catalogue No. 30932, Gambia) was used as a reference
strain. The plates were incubated at 37°C in a gas mixture
of 90% N, 5% CO2 and 5% O2 for 25-30 hours.
Growth inhibition assessment
At the end of the incubation period, suspended medium
was removed while the blood within each well was used to
make thick smears on a microscope glass slide. These
were air-dried, stained with Giemsa and examined under
microscope at ×100 magnification. The number of schi-
zonts with three or more nuclei over a total of 200 asexual
parasites was counted for each sample. All tests were
done in duplicate; the drug concentration that inhibits
schizogony by 50% (IC50) relative to the drug-free control
samples of each P. falciparum isolate were estimated from
dose-response curves by non-linear regression analysis
using GraphPad Prism
® 4.0 software package (GraphPad
Software, San Diego, CA, USA). Confidence interval (CI)
at 0.05 significance level was calculated by GraphPad
QuickCalcs (Descriptive statistics and CI of mean/Confi-
dence interval of SD) using the same software as above.
Pearson’s correlation coefficient was used to calculate the
correlation between parasite responses to the anti-malaria
drugs after entering data into Microsoft Office Excel.
Genomic DNA extraction
Genomic DNA from each sample was obtained by boil-
ing discs of the filter-paper blood blots in 150 μlo f5 0
mM NaOH with intermittent vortexing on a hot-plate
(95°C 30’); 50 μlo f1MT r i sH C lw a sa d d e dt ot h e
recovered 50 μl supernatant and the resulting mixture
directly used as template for gene amplification [30].
Sequencing of pfATPase6, pftctp, pfmdr1 and pfcrt genes
Four specific overlapping oligonucleotide primer pairs
(Table 1) were designed for genotyping significant por-
tions of the coding sequence of pfATPase6 gene [Gen-
Bank:EF564342], while a pair of primer was sufficient for
the relatively short pftctp gene [GenBank:DQ141561).
Two pairs of primer were employed in sequencing por-
tions of the pfmdr1 gene [GenBank:M29154.1] spanning
codons 86, 184, 1034, 1042 and 1246; the first pair of pri-
mer targeted the first two codons whereas the second pri-
mer set were for the last three codons (Table 1). Two
pairs of primer were also used in a nested PCR for sequen-
cing portions of the pfcrt gene [GenBank:HQ287046]
spanning codons 72-76 (Table 1). The 20 μl PCR mix con-
tained 10 μlG o T a q
® Green Master Mix, primers at
0.5 μM final concentration, and 1 μl of DNA template.
Cycling conditions for the various primer pairs are shown
in Table 1. After gene amplification, the PCR products
were run on 2% agarose gel electrophoresis to check for
the correct bands; the products were directly sequenced
with Big Dye terminator v3.1 Cycle Sequencing kit
(Applied Biosystems, CA, USA), according to manufac-
turer protocol. Sequencing analyses were done in dupli-
cates for all samples. The amplicon sequences were
aligned with published data of the NCBI database by
BLAST analysis.
For any association between molecular and in vitro
results, a threshold IC50 was set by halving the mean
IC50 for each drug and then assigning each sample at
either boundary of these values. The resulting data were
then plotted onto 2 × 2 contingency tables and calcu-
lated for significance using two-tailed Fisher’se x a c tt e s t
[28].
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Results
In vitro drug sensitivity assessment
Thirty-eight blood samples were phenotyped in vitro for
their drug sensitivities, out of which 7 (18.4%) failed the
test due to poor growth or contamination (Table 2 &
Figure 1). No parasite isolate was resistant to artesunate,
while 16/31 (51.6%) were resistant to chloroquine. The
highest IC50 value for artesunate was 3.6 nM, with geo-
metric means as follows: artesunate, 0.73 nM (95% CI,
0.38-1.08); amodiaquine, 30.69 nM (95% CI, 14.18-
47.20); chloroquine, 58.73 nM (95% CI, 38.08-79.38);
quinine, 355.37 nM (95% CI, 250.48-460.26) (Table 2).
While Pearson’s correlation coefficient between IC50
values of artesunate and amodiaquine was large (0.515),
that of artesunate and chloroquine was medium, but
were all statistically significant (Table 3). IC50 values for
artesunate and chloroquine were 3.25 and 20.71 nM
respectively for the reference strain, FCR3/FMG.
Prevalence of genetic polymorphisms in pfATPase6 and
pftctp alleles
After amplifying portions of the genes, agarose gel elec-
trophoresis of PCR products indicated that the bands
were of the expected sizes. Out of the 146 filter paper
blood blots that were collected for genotyping, 68 para-
site isolates were successfully amplified for pfATPase6
and 52 for pftctp genes; these included 34 isolates (all the
successfully tested isolates plus three unsuccessful ones)
that were used for drug sensitivity test (phenotyping). A
total of twenty point mutations were found in pfATPase6
gene (Table 4); analysis of this gene revealed a predomi-
nance of D639G in 34/68 (50%), E431K in 7/68 (10.3%),
D443E in 5/68 (7.4%) and M813Q in 5/68 (7.4%) parasite
isolates. Fisher’s exact test revealed lack of association
between D639G mutation and parasite response to arte-
sunate (p = 0.423) (Table 5). All other mutations found
Table 1 Oligonucleotide primers and PCR reaction conditions for SNPs detection in pfATPase6, pftctp, pfmdr1 and pfcrt
genes
Gene
Primer pair
Sequence 5’ ⇒ 3’ PCR product size (bp) PCR reaction conditions
pfATPase6
atp6-1F tcatctaccgctattgtatgtgg 777 94
oC5 ’ followed by 40 cycles (94°C 15’’; 55°C 30’’; 72°C 40’’); 72°C 5’
atp6-1R attcctcttagcaccactcct
atp6-2F tcaccaaggggtatcaacaa 692 94°C 5’ followed by 40 cycles (94°C 15’’; 55°C 30’’; 72°C 40’’); 72°C 5’
atp6-2R tggcataatctaattgctcttcc
atp6-3F atgtatagctgttgtaatcaacctaga 822 94°C 5’ followed by 40 cycles (94°C 15’’; 55°C 30’’; 72°C 40’); 72°C 5’
atp6-3R tcactatatggatcagcttcatca
atp6-4F ccagtacattgaatgaaaatg 605 94°C 5’ followed by 40 cycles (94°C 15’’; 55°C 30’’; 72°C 40’’); 72°C 5’
atp6-4R acgtggtggatcaataatacct
pftctp
pftctp-1F atgaaagtatttaaagacgtt 462 94°C 5’ followed by 40 cycles (94°C 15’’;
pftctp-1R ttcttctcctttataataagaat 50°C 30’’; 72°C 40’’); 72°C 5’
pfmdr1
mdr1-1F tgaacaaaaagagtaccgctga 823 94°C 5’ followed by 40 cycles (94°C 15’’; 55°C 30’’; 72°C 1’); 72°C 5’
mdr1-1R ccataccaaaaaccgaatgc
mdr1-2F caagcggagtttttgcattt 1062 94°C 5’ followed by 40 cycles (94°C 15’’; 55°C 30’’; 72°C 1’); 72°C 5’
mdr1-2R ttctctgtttttgtccacctga
pfcrt
pfcrt-1’F atggctcacgtttaggtgga 94°C 5’ followed by 40 cycles (94°C 15’’; 55°C 15’’; 72°C 40’’); 72°C 2’
pfcrt-2R aaagcttcggtgtcgttc
pfcrt-1F tgtgctcatgtgtttaaactt 94°C 5’ followed by 25 cycles (94°C 15’’; 48°C 30’’; 72°C 20’’); 72°C 5’
pfcrt-2’R ggaatagattctcttataaatcc 282
The oligonucleotide primers were supplied by Greiner Bio-One Co., Ltd. Primer pairings of pfATPase6 gene, 1F & 1R, 2F & 2R, 3F & 3R, 4F & 4R were used
resulting in the corresponding PCR product sizes. For the pfcrt primers, nested PCR was carried out with 1’F & 2R in the first reaction, followed by 1F & 2’R in the
second reaction.
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observed. One sample harboured five mutations, another
with four mutations while eight samples had three muta-
tions each, and ten samples with two mutations each.
Sequence comparisons of the pftctp gene revealed
extreme conservation as all isolates exhibited the same
identity.
Prevalence of genetic polymorphisms in pfmdr1 and pfcrt
alleles
Sixty parasite isolates were successfully amplified for both
pfmdr1 and pfcrt genes, with 34 isolates phenotyped. Fif-
teen (25%) isolates harboured the N86Y mutation (TAT
nucleotides) while 43/60 (71.7%) with Y184F mutation
(TTT nucleotides) in the pfmdr1 gene (Figure 2).
Twenty-two (36.7%) samples were double mutants and
30/60 (50%) had the single mutant Y184F. None of these
mutants was found to be associated with drug response
which was supported by Fisher’s exact test (Table 5). A
total of 29/60 (48.3%) CVIET and 31/60 (51.7%)
CVMNK, which are chloroquine-resistant and chloro-
quine-sensitive genotypes respectively were identified at
codons 72-76 of pfcrt gene. This was consistent with the
in vitro culture but there was no particular association
with artesunate response. This observation was corrobo-
rated by Fisher’s exact test (Table 5). There was no
observed correlation between pfATPase6 D638G and
pfcrt K76T with Pearson’s correlation coefficient value of
-0.178 and Fisher’s exact test of 0.738 at p = 0.05.
Discussion
The use of oral artemisinin-based monotherapies along-
side ACT is a common practice in Ghana [20], a situation
that if not monitored and controlled threatens the
Table 2 In vitro drug sensitivity of Plasmodium falciparum isolates, N=3 1
Anti- malaria drug Number of isolates (%) IC50 value (nM)
Sensitive Resistant* Lowest/Highest Geometric mean
(CI)
Standard deviation
(CI)
Artesunate 31 (100) 0 (0) 0.2/3.6 0.73
(0.38-1.08)
0.95
(0.76-1.27)
Amodiaquine 22 (71.0) 9 (29.0) 2.0/162.0 30.69
(14.18-47.20)
45.00
(35.96-60.15)
Chloroquine 15 (48.4) 16 (51.6) 2.0/200.0 58.73
(38.08-79.38)
56.30
(44.99-75.25)
Quinine 25 (80.6) 6 (19.4) 15.0/990.0 355.37
(250.48-460.26)
285.95
(228.50-382.22)
*IC50 threshold for resistance are amodiaquine 60 nM, chloroquine 100 nM and quinine 800 nM. Studies on sensitivity cut-off point for artemisinin and its
derivative is not conclusive yet but an IC50 of 20 nM is considered high [28,29]. Thirty-eight (38) samples were tested, out of which 31 (81.6%) were successfully
phenotyped with the anti-malaria drugs. Test was successful when percentage of schizont to total parasite in drug-free control well was at least 10%. Confidence
interval (CI) is at 0.05 significance level.
Figure 1 In vitro IC50 values for artesunate, amodiaquine, chloroquine and quinine for field isolates of Plasmodium falciparum.T h e
isolates have been arranged in ascending order of artesunate IC50 values; thirty-eight isolates from patients diagnosed with uncomplicated
malaria were used, out of which seven failed the tests due to poor growth/contamination.
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WHO admonishes all endemic countries to be more vigi-
lant in monitoring anti-malaria drug efficacy for early
detection of artemisinin resistance [31]. Alam et al [32]
reported on pfcrt, pfmdr1, dhps and dhfr mutations asso-
ciated with chloroquine and sulphadoxine-pyrimetha-
mine resistance and the microsatellite loci flanking these
genes in P. falciparum isolates from Ghana. There is no
report on pfATPase6 genotype from this part of the
world. In this study, we determined the prevalence of
point mutations in pfATPase6, pftctp, pfmdr1, pfcrt genes
and partly evaluated the susceptibility of P. falciparum
parasites to artesunate, amodiaquine, chloroquine and
quinine in vitro.
Studies have shown that parasites from the African
continent appear to be more susceptible to artemisinin
derivatives [28,33,34]. In this study, all field isolates of
P. falciparum that were tested exhibited satisfactory in
vitro response to artesunate, while more than half were
resistant to chloroquine. What is more important is the
presence of parasite isolates that are resistant to amodia-
quine in the phase of continual use of oral artemisinin-
based monotherapies. Ferreira et al [28] in their study
observed a strong correlation between artesunate and
amodiaquine; its significance in terms of factors that lead
t os e n s i t i v i t ym u s tb es t u d i e ds i n c et h i so b s e r v a t i o nw a s
replicated in our study. Oduro et al [35] reported on
reduced cure rate of amodiaquine in northern Ghana.
While it has been observed that persons infected with
artemisinin resistant parasites could be cured by ACT,
cure rate largely depended on efficacy of the non-artemisi-
nin component of the combination [31]. This calls for
speedy action on withdrawal of oral artemisinin-based
monotherapies from the Ghanaian market. For effective
use of these drugs in the control of malaria, there is the
need for generation of molecular epidemiological data,
ideally before the introduction of such drugs since muta-
tions could be selected by previous drug pressure. Evalua-
tion of polymorphisms in potential candidate genes of
drug resistance is of utmost importance to establishing
their role in modulating drug response, and to predicting
epidemiological dynamics of resistance.
The limitation to this study was that polymorphisms
in the pfATPase6 gene was investigated after five years
of drug (artemisinin and its derivatives) pressure in
Ghana; nonetheless, this study presents a picture in time
since there is no report of artemisinin resistance in Gha-
naian isolates. This study therefore describes for the first
Table 3 Pearson’s correlation coefficient (r) between IC50
values of the anti-malaria drugs
Anti-malaria drugs Pearson’s r Interpretation p value
artesunate vs. amodiaquine 0.515 Large < 0.001
artesunate vs. chloroquine 0.366 Medium < 0.001
artesunate vs. quinine 0.281 Small < 0.001
amodiaquine vs. chloroquine 0.308 Medium < 0.005
amodiaquine vs. quinine 0.188 Small < 0.001
chloroquine vs. quinine 0.144 Small < 0.001
Significance level was set at 0.05, while the range for interpretation of
correlation coefficient is as follows; None, 0.0 - 0.09; Small, 0.1 - 0.3; Medium,
0.3 0.5; Large, 0.5 - 1.0.
Table 4 SNPs and their corresponding amino acid point
mutations in pfATPase6 gene, N=6 8
SNP Point mutation Frequency (%) Artesunate IC50 (nM)
GGC D639G 34 (50.0) 0.2 - 3.6
*
AAA E431K 7 (10.3) 0.6 - 3.6
GAA D443E 5 (7.4) 0.6
*
CAA M813Q 5 (7.4) 0.6 - 0.9
CAT Q622H 3 (4.4) 0.3 - 3.6
GTA L402V 2 (2.9) 0.3 - 2.6
TTA F414L 2 (2.9) 0.4 - 0.8
AAT D419N 2 (2.9) 0.3
TAT C356Y 1 (1.5) 1.4
AAA R377K 1 (1.5) NA
AAA E384K 1 (1.5) NA
AAA T403K 1 (1.5) 0.2
GAA D405E 1 (1.5) 1.7
ACT A425T 1 (1.5) NA
AAA E432K 1 (1.5) NA
TCT A630S 1 (1.5) NA
GGT C645G 1 (1.5) 0.5
GGA E696G 1 (1.5) NA
AAA E710K 1 (1.5) 0.4
GGT D734G 1 (1.5) NA
*Some isolates of the corresponding nucleotide were not phenotyped, just as
NA (not applicable) represents isolates that were not phenotyped.
Table 5 Fisher’s exact test of association between
polymorphisms and in vitro drug response, N=3 1
Polymorphism vs. drug p value
pfcrt (K76T) vs. chloroquine 0.001
pfATPase6 (D639G) vs. artesunate 0.423
pfcrt (K76T) vs. artesunate 1.000
pfmdr1 (N86Y) vs. artesunate 1.000
pfmdr1 (Y184F) vs. artesunate 1.000
pfmdr1 (N86Y) vs. chloroquine 1.000
pfmdr1 (Y184F) vs. chloroquine 0.104
pfmdr1 (N86Y) vs. amodiaquine 1.000
pfmdr1 (Y184F) vs. amodiaquine 0.253
pfmdr1 (N86Y) vs. quinine 1.000
pfmdr1 (Y184F) vs. quinine 1.000
pfmdr1 (double mutant) vs. artesunate 0.577
pfmdr1 (double mutant) vs. chloroquine 1.000
pfmdr1 (double mutant) vs. amodiaquine 0.630
pfmdr1 (double mutant) vs. quinine 1.000
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By using PCR sequencing assay, neither L263E nor
S769N point mutation was observed; and this is consis-
tent with the in vitro micro-test results. A total of
twenty point mutations were observed in this gene, con-
firming its molecular diversity than previously demon-
strated [15,36,37]; these however, may be spontaneous
mutations since their role in artemisinin sensitivity is
not yet defined. D639G mutation was observed in about
half of the parasite isolates, and thus appears to be fixed
in the parasite population. This mutant is supposed to
be positioned in the cytosolic region located between
transmembrane domains 5 and 6, albeit its biological
significance is difficult to forecast in the absence of
functional analysis [29].
Even though studies have shown the involvement of
the malaria parasite pftctp gene in artemisinin activity,
our present result confirms its extreme conservation,
and thus not a strong candidate for resistance to artemi-
sinin and its derivatives due to the fact that it is not
under major selective drug pressure [14,29]. Studies
have suggested that mutant haplotypes of pfmdr1 and
pfcrt genes in some isolates conferred chloroquine resis-
tance [38,39], but however increase parasite susceptibil-
ity to artemisinin [17,18]. Our study revealed the
presence of two mutations in the pfmdr1 gene and
K76T allele in the pfcrt gene; but they had no part in
the modulation of artesunate response as the lowest and
highest artesunate IC50 values corresponded to parasite
isolates with pfcrt K76T. This was corroborated by Fish-
er’se x a c tt e s t .A f o n s oet al [40] in their study observed
that malaria parasites, such as Plasmodium chabaudi,
can develop stable resistance to artemisinin but lack
mutations in candidate genes including atp6, tctp, mdr1
and cg10.
M o r et h a nh a l fo ft h ep a r a s i t ei s o l a t e sw e r er e s i s t a n t
to chloroquine after five years of its proscription in
Ghana, which is a reflection of our molecular results but
at variance to the Malawian situation where sensitive
isolates were recovered after stopping the use of chloro-
quine [21,22]. The K76T allele was strongly associated
with this behaviour, which was confirmed by Fisher’s
exact test. This may be due to the persistent use of
chloroquine in some parts of Ghana [20].
Conclusion
Plasmodium falciparum isolates from southern Ghana
showed no improvement in susceptibility to chloro-
quine, but they exhibited satisfactory in vitro response
to artesunate. No L263E and S769N mutations in the
SERCA-type PfATPase6 were observed, albeit evidence
is clear on the greater molecular diversity of PfATPase6
than previously demonstrated as twenty mutations were
detected with D639G appearing to be fixed in this para-
site population. Whereas these mutations may be spon-
taneous and as such without any particular role in the
parasites response to artemisinin, continual monitoring
of P. falciparum susceptibility to artemisinin is welcome.
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